The U.S. Centers for Medicare and Medicaid Services (CMS) has extended its coverage of Natera's Signatera molecular residual disease test to patients with muscle invasive bladder cancer.
The decision took effect in April, and adds to existing Medicare coverage for the test for colorectal cancer and for pan-cancer immunotherapy monitoring, the company said.
